KR860006263A - 에토포시드(Etoposide)제제의 제조방법 - Google Patents

에토포시드(Etoposide)제제의 제조방법 Download PDF

Info

Publication number
KR860006263A
KR860006263A KR1019860000713A KR860000713A KR860006263A KR 860006263 A KR860006263 A KR 860006263A KR 1019860000713 A KR1019860000713 A KR 1019860000713A KR 860000713 A KR860000713 A KR 860000713A KR 860006263 A KR860006263 A KR 860006263A
Authority
KR
South Korea
Prior art keywords
etoposide
producing
weight
acid
preparation according
Prior art date
Application number
KR1019860000713A
Other languages
English (en)
Other versions
KR920003332B1 (ko
Inventor
다까시 데라다
다까시(외 4) 데라다
히데유끼 이시마도
마사루 스즈끼
미노루 나까다
겐이찌 이즈
Original Assignee
닛뽕 가야꾸 가부시기가이샤
사까노 쓰네가즈
닛뽕 가야꾸 가부시기 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닛뽕 가야꾸 가부시기가이샤, 사까노 쓰네가즈, 닛뽕 가야꾸 가부시기 가이샤 filed Critical 닛뽕 가야꾸 가부시기가이샤
Publication of KR860006263A publication Critical patent/KR860006263A/ko
Application granted granted Critical
Publication of KR920003332B1 publication Critical patent/KR920003332B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

에토포시드(Etoposide)제제의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 에토포시드(Etoposide)와 수가용성 셀루로스에테르 유도체 또는 폴리비닐피롤리돈을 함유하는 에토포시드용 액조성물을 용기에 충진시키는 단계를 포함하는 에토포시드 제제의 제조방법.
  2. 제1항에 있어서, 수가용성 셀루로스에테르 유도체가 셀루로스의 하이드록시(저급)알킬에테르; 1개 분자내에 하이드록시(저급)일킬에테르결합과 저급알킬에테르결합을 모두 갖고 있는 셀루로스에테르와 셀루로스의 저급알킬에테르로 구성되는 군으로부터 선정한 물질이고 또, 그 2% 수용액이 20℃에서 점도 2 내지 8000cps를 갖는 에토포시드 제제의 제조방법.
  3. 제1항에 있어서, 셀루로스에테르유도체 또는 폴리비닐피롤리돈의 비율이 에토포시드 1증량부에 대해 0.001 내지 0.5중량부인 에토포시드 제제의 제조방법.
  4. 제1항에 있어서, 에토포시드용액 조성물이 에토포시드함량 1 내지 16w/w%이고 또 셀루로스에테르 유도체 또는 폴리비닐피롤리돈 함량 0.002 내지 10w/w%인 에토포시드 제제의 제조방법.
  5. 제1항에 있어서, 에토포시드용액 조성물중의 용매가 저급알킬알코올, 글리콜 또는 폴리알킬렌글리콜인에토포시드 제제의 제조방법.
  6. 제5항에 있어서, 용매비율이 에토포시드 1중량부에 대해 5 내지 50중량부인 에토포시드 제제의 제조방법.
  7. 제5항에 있어서, 용매가 에탄올, 글리세롤, 프로필렌 글리콜 또는 폴리에틸렌 글리톨린 에토포시드 제제의 제조방법.
  8. 제5항에 있어서, 용매가 평균분자량 200 내지 600의 폴리에틸렌글리콜과 글리세롤의 혼합물인 에토포시드 제제의 제조방법.
  9. 제8항에 있어서, 폴리에틸렌글리콜/글리세롤 비율이 1,000/10 내지 20인 에토포시드 제제의 제조방법.
  10. 제1항에 있어서, 에토포시드용액 조성물이 에토포시드 1중량부에 대해 유기산 0.01 내지 0.2중량부를 함유하는 에토포시드 제제의 제조방법.
  11. 제10항에 있어서, 유기산의 시트르산, 타타르산, 말산, 숙신산 또는 푸말산인 에토포시드 제제의 제조방법.
  12. 4 내지 10w/w%의 에토포시드, 0.1 내지 1w/w%의 시트르산, 1 내지 5w/w%의 글리세롤, 94.8 내지 82w/w%의 폴리에틸렌글리콜과 0.1 내지 1w/w%의 하이드록시프로필셀루로스로 구성되는 에토포시드 용액 조성물로서 연질젤라틴캡슈울을 충진시키는 단계로 구성되는 에토포시드 제제의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860000713A 1985-02-19 1986-02-03 에토포시드(Etoposide)제제의 제조방법 KR920003332B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31203 1985-02-19
JP60031203A JPS61189230A (ja) 1985-02-19 1985-02-19 エトポシド製剤

Publications (2)

Publication Number Publication Date
KR860006263A true KR860006263A (ko) 1986-09-09
KR920003332B1 KR920003332B1 (ko) 1992-04-27

Family

ID=12324856

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860000713A KR920003332B1 (ko) 1985-02-19 1986-02-03 에토포시드(Etoposide)제제의 제조방법

Country Status (10)

Country Link
US (1) US4734284A (ko)
EP (1) EP0193287B1 (ko)
JP (1) JPS61189230A (ko)
KR (1) KR920003332B1 (ko)
AU (1) AU583585B2 (ko)
DE (1) DE3671372D1 (ko)
DK (1) DK165902C (ko)
ES (1) ES8704727A1 (ko)
HU (1) HU196707B (ko)
MX (1) MX9202976A (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
GB8629639D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
US4927638A (en) * 1986-10-08 1990-05-22 Bristol-Myers Company Etoposide solutions
US4772589A (en) * 1986-10-29 1988-09-20 Bristol-Myers Etoposide solution in NMP
GB8629640D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
CA2017916C (en) * 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5919481A (en) * 1996-06-28 1999-07-06 Ncneil-Ppc, Inc. Fill material for soft gelatin pharmaceutical dosage form
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
PT1666026E (pt) * 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
AU2001232344A1 (en) * 2000-02-21 2001-08-27 Fujisawa Pharmaceutical Co. Ltd. Liquid preparation with improved absorbability
ES2302926T5 (es) 2002-04-25 2012-08-23 Banner Pharmacaps, Inc. Cápsula blanda masticable
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
WO2019133791A1 (en) * 2017-12-28 2019-07-04 Ackler Scott Formulations, systems, and methods for therapeutic treatment
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH514578A (de) * 1968-02-27 1971-10-31 Sandoz Ag Verfahren zur Herstellung von Glucosiden
ZA728764B (en) * 1971-12-29 1973-08-29 Squibb & Sons Inc One piece gelatin capsules containing chloral hydrate
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
DE3200766A1 (de) * 1981-01-14 1982-09-16 Toyo Jozo Kk Praeparat mit ausgezeichneter absorptionseigenschaft
JPS6032799A (ja) * 1983-07-29 1985-02-19 Microbial Chem Res Found 新規４′−デメチル−４−エピポドフィロトキシン誘導体
NZ211078A (en) * 1984-03-19 1987-08-31 Bristol Myers Co Oral dosage form of etoposide
JPS60239418A (ja) * 1984-05-15 1985-11-28 Nippon Kayaku Co Ltd エトポシド軟カプセル製剤
US4609644A (en) * 1984-06-15 1986-09-02 St. Jude Children's Research Hospital Epipodophyllotoxinquinone glucoside derivatives, method of production and use

Also Published As

Publication number Publication date
HUT43953A (en) 1988-01-28
DK165902B (da) 1993-02-08
MX9202976A (es) 1992-07-01
EP0193287B1 (en) 1990-05-23
JPS61189230A (ja) 1986-08-22
DK75886A (da) 1986-08-20
ES552067A0 (es) 1987-04-16
DK75886D0 (da) 1986-02-18
EP0193287A2 (en) 1986-09-03
KR920003332B1 (ko) 1992-04-27
AU5279386A (en) 1986-08-28
DK165902C (da) 1993-06-28
HU196707B (en) 1989-01-30
DE3671372D1 (de) 1990-06-28
JPS6366810B2 (ko) 1988-12-22
EP0193287A3 (en) 1986-10-08
US4734284A (en) 1988-03-29
ES8704727A1 (es) 1987-04-16
AU583585B2 (en) 1989-05-04

Similar Documents

Publication Publication Date Title
KR860006263A (ko) 에토포시드(Etoposide)제제의 제조방법
KR860009032A (ko) γ-사이클로 덱스트린 유도체의 제조방법
KR870002842A (ko) 싸이클로덱스트린으로 제조되는 7-이소프로폭시-이소플라본의 함유착물과 그를 활성성분으로 함유하는 약리학적 조성물 및 제제
ATE18863T1 (de) Verfahren zur herstellung freifliessender ethyl- cellulose-mikrokapseln.
KR900701251A (ko) 약제학적 피막 형성 조성물
KR870006901A (ko) 인터로이킨-2 조성물의 제조방법
CA1166579A (en) Hydrocolloid containing paste-like composition
GB1493930A (en) Agents for the shampooing and treatment of hair
CA2011943A1 (en) Compositions for the preparation of dosage-form active vitamins d3 and process for preparing stable dosage-form active vitamins d3 by using the same
PT76219A (en) Process for the preparation of a fabric softening composition including an aqueous base a cationic lanoline softener and a viscosity control agent
ATE53296T1 (de) Spritzfertige, waessrige, alkalische injektionsloesung von torasemid und verfahren zu ihrer herstellung.
BE905528A (fr) Compositions antibiotiques.
KR850003394A (ko) 신규의 벤젠설포닐-락탐을 활성물질로서 포함하는 약학적 조성물과 그 제조방법
JPS5670028A (en) Polymer bonding with albumin
ATE67507T1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4170655A (en) Stable aqueous or aqueous-alcoholic solutions of fat-soluble perfume oils or drugs containing hydroxyalkyl ester- or N-(hydroxyalkyl) amide-ethoxylates
KR910021361A (ko) 항궤양 물질
US1953741A (en) Reaction products of glycols and boric acid and method of producing the same
US2165997A (en) Process of preparing fire-extinguishing foam
KR910000166A (ko) 에토포시드 제제
KR880003621A (ko) 의약 제제물
US2161407A (en) Stable solutions of sulphanilamide
GB1009233A (en) Thin film coating for tablets and the like and method of coating
US4186207A (en) Stable aqueous or aqueous-alcoholic solutions of fat-soluble perfume oils or drugs containing N-(hydroxyalkyl)amide-ethoxylates
JPS63280024A (ja) 冠循環活性作用剤、これを含有するゼラチン‐噛みカプセル及び舌下‐スプレー

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050222

Year of fee payment: 14

EXPY Expiration of term